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ABSTRACT
INTRODUCTION:
Hormone receptor status plays a very important role in deciding the need 
for appropriate hormonal therapy post surgically for patients with carcinoma 
breast and hence serves as an important prognostic factor. This study is done to
determine the incidence of the three receptors namely Estrogen Receptor (ER), 
Progesterone Receptor (PR) and Her2/neu Receptor in women who underwent 
mastectomy for breast cancer in RGGGH, Chennai.
AIMS AND OBJECTIVES:
To study the incidence of receptor status in patients who underwent 
mastectomy for carcinoma breast in Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai.
PLACE OF STUDY:
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai.
MATERIALS AND METHODS:
200 women who underwent mastectomy for carcinoma breast in my 
institution during 2012-2014 and had their specimen analysed for receptor status 
were included in the study. 120 belonged to premenopausal and 80 belonged to 
the postmenopausal age group. The parameter analysed was the presence or 
absence of the receptors either singly or in combination using special kits.
OBSERVATIONS AND CONCLUSIONS:
The incidence of Estrogen receptor positivity was found to be 57%. It 
was higher in premenopausal women (63.33%), whereas in postmenopausal 
women it was 47.5%. 
The incidence of Progesterone receptor positivity was 32.5%. It was 
higher in postmenopausal women (36.25%) compared to premenopausal women 
(30%). 
The incidence of Her2/neu receptor positivity was found to be 32.5%. It 
was equally distributed in premenopausal and postmenopausal women (32.5%).
The incidence of Triple negative receptor status was found to be 16%.
CONTENT
 Introduction
 Aim of the study
 Review of literature
 Materials and methods
 Observation and analysis
 Discussion
 Conclusion
 Bibliography
 Patient consent form
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INTRODUCTION 
Breast cancer is the most common of all cancers and is the leading 
cause of cancer deaths in women worldwide, accounting for about 1.5% 
of all deaths. A recent study in India revealed that 1 in 28 women develop 
breast cancer during their lifetime. This is higher in urban areas 
accounting for 1 in 22 women compared to rural areas where it is much 
lower at 1 in 60 women. In India, the average age of the high risk group is 
43-47 years, whereas in the west, those aged 53-57 yearsare more prone. 
The overall incidence of breast cancer is on the rise as a result of 
increase in the life span, lifestyle changes and improved survival from 
other diseases. Despite this, the mortality is on the decline as a result of 
early detection by screening and improvements in therapy. Current 
treatment is guided by insights into breast cancer biology with an increase 
in the ability to define disease biology and status in individual patients 
and the availability of improved treatment modalities. 
This is a prospective and retrospective observational study 
conducted at Rajiv Gandhi Government General Hospital, Chennai. The 
receptor status (namely ER, PR, HER 2 neu) of mastectomy specimen of 
those women operated for carcinoma breast were obtained and analyzed 
to determine the incidence of receptor status in the study population. 
 
 
 
 
 
AIM OF THE STUDY 
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AIM OF THE STUDY 
 
To study the incidence of receptor status in patients who underwent 
mastectomy for carcinoma breast in Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai. 
  
 
 
 
 
 
REVIEW OF 
LITERATURE 
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BRIEF SURGICAL HISTORY 
· In 1600 B.C., Ebers Papyrus suggested heat cauterization of breast 
tumors. 
· In 525 B.C., Democedes successfully treated a woman with breast 
cancer. 
· In  early  5th and  late  4th century B.C., Hippocrates made detailed 
references to breast cancer and its effects. 
· In 2nd century A.D., Galen claimed that melancholia caused cancer. 
Treatment centered on nutrition and purgation. Surgical excision 
was only recommended if tumor was removable. 
· In 1550s, Vesalius did wide excision and used ligatures for 
hemostasis. 
· In 1560, Ambroise Pare recognized the relation between breast 
cancer and axillary node involvement. 
· 1n 1786, Cruikshank described lymphatic drainage of breast. 
· In 1845, Astley Cooper identified the suspensory ligaments of the 
breast which were named after him. 
· In 1867, Moore proposed that local recurrence after breast 
amputation was due to disseminated fragments not removed at the 
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time  of  surgery.  He  suggested  removal  of  breast  along  with  the  
surrounding tissues. 
· In 1870, Lister supported and refined Moore’s technique of axillary 
exposure and divided pectoral muscles. 
· In 1875, Volkmann proposed wide excision of breast along with 
the skin and pectoral fascia. In advanced cases, he removed 
pectoralis major and sometimes pectoralis minor muscle. 
· In 1878, Billroth did lumpectomy for early breast cancer. 
· In 1882, Halstead described radical mastectomy. He did axillary 
clearance in all cases and also removed the pectoralis major muscle 
in most of them giving wide margin of clearance. 
· In 1885, Sappey noted the presence of sub areolar plexus into 
which parenchymal lymphatics drained, claiming that most of the 
drainage was to the axilla. 
· In 1891, Welsh used frozen sections in the diagnosis of breast 
cancer. 
· In 1895 , Czerny replaced a surgically removed breast with a large 
lipoma  
(Breast reconstruction) 
 5 
 
· In 1896, Tansini performed immediate breast reconstruction with 
Lattissmus Dorsi musculocutaneous flap after radical mastectomy. 
· In 1897, Gocht irradiated a case of inoperable breast cancer. 
· In 1899, Rotter noted metastasis while tracing lymphatics from 
breasts to interpectoral nodes. 
·  In 1918, Stibbe published detailed study on internal mammary 
lymphatics. 
· In 1927, Handley suggested standard radical mastectomy be 
extended to include internal mammary lymphatics. He also 
implanted Radium tubes parasternally as prophylaxis. 
· In 1938, Gershon-cohen recommended screening for breast cancer. 
· In 1943, Patey and Dyson developed Modified Radical 
Mastectomy. They advocated wide skin incision and axillary 
clearance while sparing pectoralis major muscle. 
· In 1948, McWhirter promoted the combination of simple 
mastectomy and high voltage x-ray therapy. 
· In 1960, Egan described the modern mammography. 
· In 1963, Dodd et al. performed the first needle – localization 
procedure. 
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· In 1965, Auchincloss and Madden described radical mastectomy 
preserving both pectoral muscles. 
· In 1977, Dreaver pioneered breast reconstruction with 
myocutaneous flaps. 
· In 1978, Bostwick described and popularized the use of Lattissmus 
Dorsi myocutaneous flap. 
· In 1981, Turner and Maddox reported trials comparing radical vs 
modified radical mastectomy, finding no difference in survival. 
· In 1981, breast conservation surgery was described. 
· 1n 1992, Krag and Guiliano published the development of sentinel 
lymph node mapping in carcinoma breast. 
· In 1994, BRCA1 wasdiscovered. 
· In 1995, BRCA2 was discovered. 
· In 2007, Bevacizumab was introduced as an adjuvant treatment in 
carcinoma breast.  
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EMBRYOLOGY 
‘MILK LINE’ OF SCHULTZ 
 
The breast is a group of large glands derived from the epidermis. 
 During the second month of gestation, two bands of thickened 
ectoderm appear on the ventral body wall extending from the axilla to the 
groin. 
 In humans, only the pectoral portion of the bands will persist and 
develop into adult mammary glands. 
 The glandular portion of the breast is derived from the ectoderm. It 
arises from local thickening of the epidermis from which 16 – 24 buds of 
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cells grow into the underlying mesoderm during the twelfth week. These 
ducts will become canalized near term to form lactiferous ducts. 
 The connective tissue stroma is derived from the mesoderm which 
also gives rise to dermis of the skin and the superficial fascia. Fibres 
forming the suspensory ligaments will develop from both the layers. This 
and the appearance of fat in the superficial fascia does not occur until 
puberty. 
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ANATOMY OF THE BREAST 
 
 
· The female breast lies in the subcutaneous tissue (superficial fascia) of 
anterior thoracic wall. 
· It extends from the sternal edge to near the mid-axillary line 
horizontally and from second to sixth ribs vertically. 
· However, mammary tissue may extend from the clavicle to seventh or 
eighth ribs and from the midline to the anterior edge of lattissmus 
dorsi. 
· It overlies the pectoralismajor, overlapping onto the serratus anterior 
and a small part of rectus sheath and external oblique muscle. 
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· A small extension of the upper outer quadrant towards the axilla is 
called the Axillary Tail of Spence. It may pass through a defect in the 
pectoral fascia called the Foramen of Langer which lies at the level of 
third intercostal space. It may be mistaken for an enlarged node or a 
lipoma. 
· The breast is separated from the underlying muscle by a condensation 
of the superficial fascia called the pectoral fascia. 
· Strands of fibrous tissue connecting the dermis and the pectoral fascia 
running through the breast parenchyma are called the suspensory 
ligaments(Cooper’s ligaments). They help to maintain the 
protuberance of the young breast. 
· Behind the breast is the Retro mammary space(Chassaignac’s bursa). 
It is bound anteriorly by the deep layer of superficial fascia and 
posteriorly by the pectoral fascia. It contains loose areolar tissue and 
aids in the mobility of the breast on the chest wall. 
· A lobule is the basic structural unit of the breast. They are more 
numerous in young women. They empty via ductules into the 
lactiferous ducts. These ducts are lined by contractile myoepithelial 
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cells and provided with a terminal dilation called the ampulla / 
lactiferous sinus, which serves as a reservoir for milk. 
· About 15-20 lactiferous ducts, each draining a lobe, converge in a 
radial direction to open individually on the tip of the nipple, a 
projection just  below the center  of  the breast,  which contains smooth 
muscle fibres. 
· The nipple is surrounded by circular pigmented skin called the Areola, 
which contains involuntary muscles. 
· The areolar epithelium contains numerous sweat and sebaceous 
glands, the latter of which enlarge during pregnancy to form the 
Montegomery’s tubercles. 
· The male breast has no lobules or alveoli. The small nipple and areola 
overly the fourth intercostal space. 
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ANATOMY OF THE AXILLA 
· It  is  a  pyramidal  space  between  the  upper  arm  and  the  side  of  the  
thorax containing neurovascular structures and lymph nodes. 
· It is bounded in front and behind by the axillary folds and 
communicates above with the posterior triangle of the neck. 
· The anterior wall is formed by pectoralis major, pectoralis minor, 
subclavius muscles and the clavipectoral fascia. 
· The posterior wall is formed by the teres major, latissimus dorsi and 
subscapularis muscles. 
· The medial wall is formed by the upper four ribs and the intercostal 
muscles and the upper digitations of serratus anterior muscle. 
· The lateral wall is formed by the intertubercular sulcus of the 
humerus related to the biceps brachii and coracobrachialis muscles. 
· The apex is bounded by the superior border of scapula, outer border of 
first rib and posterior border of the clavicle; it forms the channel of 
communication between the neck and axilla. 
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· The floor is formed by the axillary fascia, which extends from the 
anterior to the posterior axillary folds and from the fascia over serratus 
anterior to deep fascia of the arm, and the skin. 
· CONTENTS: 
- Axillary vessels,  
- Infraclavicular part of brachial plexus,  
- Long thoracic nerve,  
- Intercostobrachial nerve ,  
- Axillary lymph nodes and  
- Axillary pad of fat. 
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AXILLARY LYMPH NODES 
· They are around 50 in number. 
· They are divided into 3 levels 
- Level 1à lateral to pectoralis minor 
- Level 2à behind pectoralis minor 
- Level 3à medial to pectoralis minor 
1. Anterior or pectoral group 
- Lie behind anterior pectoral fold , along lateral thoracic 
vessels 
2. Posterior or subscapular group 
- Lie in relation to the posterior fold, along subscapular 
vessels. 
3. Lateral group 
- Along medial side of Axillary vein 
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4. Central group 
- Situated in the fat of axilla 
5. Interpectoral ( Rotter’s node ) 
- Between pectoralis major and minor. 
6. Apical group 
- At the axillary apex. 
 
AXILLARY NODES 
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BLOOD SUPPLY OF BREAST: 
· Branches from lateral thoracic artery  
· Perforating branches of internal thoracic artery 
· Lateral branches of posterior intercostal arteries 
· Occasionally, a branch from the Pectoral branch of thoraco-
acromian artery. 
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VENOUS DRAINAGE OF BREAST: 
· Occurs mainly to the axillary and internal thoracic veins via 
veins from glandular tissue and circumareolar venous plexus. 
· Some drainage occurs to the posterior intercostal veins, which 
provides a link to the internal vertebral venous plexus serving a 
pathway for metastatic spread to the bone. 
LYMPHATIC DRAINAGE OF THE BREAST 
· A sub areolar plexus (Sappey’s plexus) of lymphatics communicates 
with lymphatics within the breast parenchyma. 
· About75 % of the drainage passes to the axillary nodes mainly the 
anterior group. 
· Much of the rest, originating particularly from the medial part, drain 
into the internal mammary nodes. 
· A few drain into the posterior intercostal nodes. 
· Occasionally, some may drain into the interpectoral, infraclavicular 
and supraclavicular nodes. 
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· The superficial lymphatics have connections with that of the opposite 
breast and the anterior abdominal wall via which lymph may drain 
into posterior mediastinal nodes. 
· The minor pathways convey lymph only when the major lymph 
channels are blocked by malignant disease. 
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NORMAL DEVELOPMENT AND PHYSIOLOGY 
The breast development (Thelarche) begins between the ages of 9 
and 12 years. 
It is initiated by low amplitude pulses of pituitary gonadotropins 
which in turn increase the serum estrogen levels. 
It is characterized by increased fat deposition, new duct formation 
and appearance of lobular units which is under the control of pituitary 
hormones, estrogen, progesterone, adrenal hormones, insulin & 
thyroxine. 
The mature post pubertal breast comprises of stroma, lobular units, 
lactiferous ducts and fat. 
During phases of menstrual cycle, the stroma and duct epithelium 
undergo cyclic stimulation resulting in alteration of morphology and 
hypertrophy. There is fluid accumulation and intralobularedema in late 
luteal phase which accounts for the breast engorgement and pain. 
Pregnancy and lactation result in ultimate breast development 
under the influence of progesterone, prolactin and placental lactogen, 
which stimulate the development of secretory alveoli. 
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During lactation, prolactin causes secretion of milk proteins and 
lipids. Milk ejection occurs in response to neural stimulation initiated by 
sucking activity which causes release of oxytocin resulting in contraction 
of myoepithelial cells 
When nursing ceases, prolactin levels fall and the non-ejected milk 
effects the cessation of milk production. The alveoli regress and the duct 
system returns to the non-pregnant state. 
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ANOMALIES OF THE BREAST 
· AMAZIA 
 Absence of breast. May be associated with Turner’s syndrome, 
congenital adrenal hyperplasia. POLAND SYNDROMEà constellation of 
amastia, absent sternocostal head of pectoralis major, syndactyly, 
nephropathy. 
· ATHELIA 
 Absence of nipple. 
· POLYMASTIA or POLYTHELIA    
 supernumerary breasts or nipples may develop along the ‘milk 
line’, most commonly in the inframammary fold region. It is due to 
incomplete involution of mammary ridge. 
· AMASTIA 
Complete absence of breast tissue, nipple and areola. 
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· ABERRATIONS OF NORMAL DEVELOPMENT AND 
INVOLUTION  (ANDI): 
It occurs due to disturbance in cyclic hyperplasia or involution 
changes that occur in the breast, often bilateral. 
It is seen in the 3rd and 4th decades of life. 
It is common in spinster, nullipara and those who have not breast 
fed. 
Its pathogenesis is not clear and wide range of processes occur 
such as fibrosis, adenosis, epitheliosis, cystic changes and inflammation 
in varying proportions on combinations. 
The process begins with periductal fibrosis, probably secondary to 
estrogen stimulation, which causes irritation of cells lining the ducts and 
epithelial proliferation. Progressive epithelial clumping gives a gland-like 
appearance (adenosis) and obstruction to duct drainage causes cystic 
changes. 
Its premalignant potential is debatable and the higher incidence of 
malignancy may be related to continued estrogen stimulation, which is 
common to both the conditions. 
The various changes seen in different age groups are given below. 
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EARLY REPRODUCTIVE YEARS (15 – 25 YEARS) 
 NORMAL 
§ Lobular development 
§ Stromal development 
§ Nipple eversion 
DISORDER 
§ Fibro adenoma 
§ Adolescent hypertrophy 
§ Nipple inversion 
DISEASE 
§ Giant fibro adenoma 
§ Gigantomastia 
§ Sub areolar abscess 
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LATER REPRODUCTIVE YEARS (25 - 40 YEARS) 
 NORMAL 
w Cyclical menstrual changes 
w Nodularity 
w Epithelial hyperplasia of pregnancy 
DISORDER 
w Cyclical mastalgia 
w Bloody nipple discharge 
DISEASE 
w Incapacitating mastalgia 
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INVOLUTION (35 – 50 YEARS) 
NORMAL 
w Involution of lobules 
w Involution of ducts 
w Epithelial turnover 
DISORDER 
w Duct ectasia 
w Nipple retraction 
w Epithelial hyperplasia 
DISEASE 
w Periductal mastitis 
w Epithelial hyperplasia with atypia 
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RELATIVE RISK FOR BREAST CANCER DEVELOPMENT IN 
ANDI 
v NON PROLIFERATIVE – NO INCREASED RISK 
§ Microcysts/ macrocysts 
§ Duct ectasia 
§ Simple fibroadenoma 
§ Mastitis, Fibrosis 
§ Apocrine metaplasia, Squamous metaplasia 
§ Mild hyperplasia 
v PROLIFERATIVE – RR 1.5 TO 2.0 
§ Complex fibroadenoma 
§ Ductal papilloma 
§ Sclerosing adenosis 
§ Hyperplasia – moderate/severe 
v PROLIFERATIVE DISEASE WITH ATYPIA – RR >2 
§ Atypical ductal  hyperplasia 
§ Atypical lobular hyperplasia 
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BREAST CANCER 
CLASSIFICATION 
NON-INVASIVE EPITHELIALCARCINOMAS: 
· Lobular carcinoma in situ 
· Ductal carcinoma in situ 
- Papillary type 
- Solid type 
- Cribriform type 
- Comedo type 
INVASIVE EPITHELIAL CARCINOMAS: 
DUCTAL 
· Invasive Ductal carcinoma, NOS (not otherwise 
specified) 
· Medullary carcinoma 
· Mucinous or colloid carcinoma 
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· Tubular carcinoma 
· Papillary carcinoma 
· Scirrhous carcinoma 
· Comedo carcinoma 
· Inflammatory carcinoma 
· Adenoid cystic carcinoma 
· Metaplastic carcinoma 
LOBULAR 
· Invasive with predominant in situ component 
· Invasive Lobular carcinoma 
NIPPLE 
§ Paget’s disease, NOS 
§ Paget’s disease with intraductal carcinoma 
§ Paget’s disease with invasive ductal carcinoma 
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MIXED CONNECTIVE AND EPITHELIAL CANCERS 
§ Cystosarcoma phylloides 
§ Angiosarcoma 
§ Carcinosarcoma 
§ Adenocarcinoma 
RISK FACTORS FOR CARCINOMA BREAST 
LOW RISK 
ü Early menarche 
ü Late menopause  
ü Nulliparity 
ü Hormone replacement therapy 
ü Alcohol use 
ü Smoking 
ü Post- menopausal obesity 
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INTERMEDIATE RISK 
ü First degree relative with breast cancer 
ü Late age at first child birth 
ü CHEK 2 mutation 
ü Proliferative breast disease 
HIGH RISK 
ü BRCA 1 or BRCA 2 mutation 
ü LCIS 
ü Atypical ductal / lobular hyperplasia 
ü Radiation exposure before 40 years 
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DUCTAL CARCINOMA IN SITU (DCIS) 
 It is the most common type of non-invasive breast cancer 
consisting of malignant ductal epithelial cells which have not extended 
beyond the basement membrane. 
It accounts for up to 25% of newly diagnosed breast cancers. 
It comprises of a heterogeneous group of histopathological lesions 
classified based on architectural patterns, namely: micro papillary, 
papillary, solid, cribriform and comedo. 
Very few cases present as a palpable mass and most commonly 
presents with discharge from the nipple. 
 Papillary and cribriform types are low grade lesions, whereas solid 
and comedo types are high grade lesions and associated with higher risk 
of invasive cancer. 
Majority are diagnosed by mammography. The most common 
mammographic findings are calcifications (90%), which arise from 
intraductal debris formed by necrotic tumour cells and other debris. In 
10% of cases, may present as soft tissue abnormalities as in invasive 
cancer. 
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 The degree of atypia and presence of necrosis mainly determine the 
grade of malignancy which is given by Van Nuys Prognostic Index. It 
also takes into account the tumour size, resection margin and patient’s 
age. 
LOBULAR CARCINOMA IN SITU (LCIS) 
 It accounts for up to 15% of in situ cancers. 
 It is characterized by neoplastic cells which are confined to the 
lobules of the breast preserving their architecture. 
 It is asymptomatic and not detected by a mammogram. 
 It comes to attention only after a biopsy performed for some other 
reason. 
 It is frequently bilateral (40%) and mostly multicentric (70%). 
 It serves as a marker for identifying women at increased risk for 
development of subsequent invasive cancer, which is mostly ductal rather 
than lobular. The risk extends more than 20 years and is greater for the 
ipsilateral breast. 
 It is one of the indications for bilateral prophylactic mastectomy 
due to the above risk of cancer development in either of the breasts. 
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INVASIVE BREAST CANCER 
 When the neoplastic cells invade through the basement membrane 
into the stroma, it constitutes invasive breast cancer. 
 It is characterized histologically by lack of overall architecture, 
haphazard infiltration of cells into the stroma, formation of sheets of cells 
without conforming to form and function. 
 It is broadly divided into 2 groups: Invasive ductal and lobular 
cancers. 
 The most common type is the Invasive ductal carcinoma, not 
otherwise specified (NOS) type, which accounts for 50 – 70% of all breast 
cancers. The malignant cells don’t take on special features as seen in the 
following types. 
 Tubular carcinoma is composed of infiltrating cells arranged in 
small glands lined by a single row of flat epithelium. 
 Mucinous or colloid carcinoma is characterized by secretion of 
copious amount of mucin by the tumor cells. 
 The above two types are low grade lesions and constitute about 2-
3% of all breast cancers each. 
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 Medullary carcinoma is characterized by malignant cells arranged 
in a syncytial fashion surrounded by an infiltrate of lymphocytes. It is a 
high grade type constituting about 5% of all breast cancers. 
 Invasive lobular carcinoma accounts for 10% of all breast cancers 
and is characteristically often bilateral and multicentric. It is the second 
most common histological subtype of breast cancer. It is of intermediate 
grade. 
 Inflammatory breast carcinoma is  the  most  aggressive  of  all  
subtypes comprising about 5% of breast cancers. It is characterized by 
infiltration of the dermal lymphatic channels by infiltrating tumour cells. 
It is usually not associated with a breast lump making the diagnosis 
difficult. It manifests as edema, erythema, brawny induration and warmth 
mimicking breast abscess and hence at risk of being misdiagnosed.  
 Paget’s disease accounts for about 1% of all breast cancers. It is 
characterized by malignant cells invading into the lactiferous sinuses onto 
the epidermis of the nipple. It presents with nipple erythema and irritation 
which progresses to ulceration and crusting. It is associated with an 
underlying breast cancer in >90% of cases. It is characterized by the 
presence of Paget’s cells which are large pale staining cells with round or 
oval nucleus and a large nucleolus. It is managed by mastectomy or wide 
excision followed by radiotherapy. 
 35 
 
FAMILIAL BREAST CANCER 
 Genetic factors account for about 5-10% of all breast cancer cases. 
 The most important genes are BRCA1 and BRCA2. 
 BRCA1 is a tumour suppressor gene located in chromosome 17. 
Mutations in this gene is responsible for up to 40% of familial breast 
cancers and is associated with up to 50% lifetime risk of ovarian cancer 
as well. These tumours tend to have a poor prognosis. 
 BRCA2 gene is located on chromosome 13 and its mutation 
accounts for 30% of familial breast cancers and 25% life time risk for 
ovarian cancer. It is also related to male breast cancer. These tumours 
tend to have a better prognosis compared to those with BRCA1 
mutations. 
 Other predisposing genes include p53, PTEN, ATM, CHEK2, 
BRIP1, NBS1, RAD50, MSH2 and MLH. 
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SPREAD OF BREAST CANCER 
LOCAL SPREAD 
· to skin 
· to pectoralis major muscle 
· to chest wall 
 This can be identified by testing the fixity of the lump to the above 
structures by looking for cutaneous manifestations, restricted mobility on 
putting muscle into contraction or even at resting state and inability of the 
breast to fall forward on bending down. 
HEMATOGENOUS SPREAD 
· Bones à vertebrae (lumbar and dorsal), ribs, skull, ends of 
long bones; forming osteolytic metastasis. 
· Liver 
· Lungs 
· Brain 
· Adrenals, Ovaries 
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LYMPHATIC SPREAD 
§ Occurs primarily to the axillary nodes, particularly the 
anterior group. 
§ Tumours in the posteromedial aspect drain into the internal 
mammary nodes. 
§ Through dermal lymphatics, spread to contralateral nodes 
can occur. 
§ Involvement of supraclavicular and contralateral axillary 
nodes indicates advanced disease. 
§ Involvement of contralateral axillary nodes indicates 
metastatic breast cancer. 
§ Lymph node involvement serves as a marker for the 
metastatic potential and is the most important prognostic 
factor determining the outcome. 
 
 
  
 38 
 
CLINICAL PRESENTATION 
w Lump in the breast most commonly in the upper outer quadrant 
(50%) 
w Recent Retraction of the nipple. 
w Discharge from the nipple  
- Watery / bloody. 
w Skin manifestations. 
w Features of distant metastasis 
- Back pain/ bone pain/spontaneous fractures/ 
paraplegia 
- Dyspnea / cough with hemoptysis 
- Jaundice  
- Seizures 
- Headache 
- Krukenberg tumour 
w Loss of appetite 
w Loss of weight. 
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CUTANEOUS MANIFESTATIONS 
ü Puckering / Dimpling of skin 
- Due to infiltration of cooper’s ligaments. 
ü Retraction of nipple 
- Due to infiltration of lactiferous ducts. 
ü Peau d’orange appearance  
- Due to obstruction of dermal lymphatics by tumour 
cells, the openings of hair follicles get buried in the 
oedema giving an orange peel like appearance. 
ü Skin ulceration / fungation / Satellite nodules 
ü Nipple ulceration / scaling 
ü Cancer-en-cuirasse 
- Multiple cancerous nodules & thickened skin like a 
coat of armour over chest & arms. 
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INVESTIGATIONS 
‘TRIPLE ASSESSMENT’ 
1. Clinical examination 
2. Radiological imaging 
USG (young female) 
Mammography (older age) 
MRI 
3. Pathological examination 
FNAC 
Trucut / Core needle biopsy 
Surgical biopsy 
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v MAMMOGRAPHY 
· It  is  a  plain  x-ray  of  breast  soft  tissue  taken  using  low  
voltage(40 kV) and high ampere(300 mA) x rays 
· Breast  is compressed between two plexi glass  plates to: 
- Even out the thickness 
-   Spread out tissue to decrease obscuration. 
-   Lower x ray dose 
-   Hold the breast still  
-   Decrease x ray scatter 
· 2 views are taken : 
- Medio lateral oblique  
- Craniocaudal 
· Dose of radiation is 0.1cGY and is quite safe. 
· It  is  suited  for  older  women  as  the  breast  is  less  dense  (Fat  
absorbs little radiation & provides contrasting background for 
detection of small lesions.) 
 
· Used for screening as well as diagnostic purposes 
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· It can be used for taking guided biopsy as in stereotactic core 
needle biopsy. 
w Findings suggestive of malignancy: 
o  Mass effect 
o  Architectural distortion 
o  Loss of symmetry 
o  Micro-calcification  
o  Branching  calcification 
o  Clustering  
o  Spiculation  
BIRADS GRADING: (Breast Imaging Reporting AndData System) 
w Grade I     : Normal 
w Grade II    : Benign 
w Grade III   : Probably Benign 
w Grade IV   : Suspicious of Malignancy 
w Grade V    : Highly suggestive Malignancy 
w Grade VI   : Biopsy Proven Malignancy 
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DISADVANTAGE:  
w Sensitivity is low in younger women as the breast is dense.  
w Fails to detect15% of all palpable cancerous lumps.  
w Thus a normal mammogram doesn’t exclude the presence of 
carcinoma. 
NEWER ADVANCES 
• Digital mammography 
• Computer aided detection 
• Contrast enhanced mammography 
• Tomosynthesis/ 3D mammography 
• Xeromammography 
• Optical mammography 
 These techniques help to delineate the lesions better and provide 
improved contrast enhancement. 
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v ULTRASOUND BREAST 
- It is suited for young women with dense breasts. 
- Its main use is to distinguish cystic from solid lesions. 
- It has the highest sensitivity for axillary node detection.  
- USG guided percutaneous biopsy of axillary nodes/lesions can 
be performed  
DISADVANTAGE:  
· It is highly operator dependent  
· It is not used in screening as it fails to detect calcifications 
and misses a large number of cancers. 
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v MRI BREAST 
It is used to  
w Identify primary tumour in pts presenting with axillary 
lymphadenopathy without mammographic evidence of a primary 
tumour. 
w For evaluating invasive lobular cancers. 
w Useful to distinguish scar from recurrence in women who have had 
BCS for carcinoma previously. 
w Useful as a screening tool in high risk women 
w Best imaging modality of choice in women with breast implants. 
w Used in taking guided biopsies. 
Sensitivity varies from 60 % for DCIS to >90 % for invasive breast 
cancers. 
DISADVANTAGE: 
Less useful than USG in the management of axilla in both primary 
breast cancer as well as in recurrent breast cancers. 
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v FNAC(FINE NEEDLE ASPIRATION CYTOLOGY) 
  In FNAC, Cytology is obtained using 21G/23G needle and 
10ml syringe with multiple passes in the lump with negative pressure in 
syringe. Aspirate is then smeared on to slide, air dried, fixed. 
ADVANTAGES: 
§ Simple procedure 
§ Results can be obtained faster 
DISADVANTAGES:  
§ High false positive and false negative results 
§ Invasive carcinoma cannot be differentiated from in-situ 
carcinoma. 
§ Does not provide information regarding the hormone receptor 
status. 
USES: 
w In recurrent breast cancer, 
w For axillary nodes, 
w In cases of diagnostic uncertainty. 
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v TRUCUT BIOPSY 
 Advantages over FNAC: 
•  Definitivediagnosis can be obtained. 
•  Helps to distinguish between invasive carcinoma and  in situ 
carcinoma 
•  Useful in assessing the receptor status for hormone therapy. 
v EXCISION BIOPSY 
It is done in place of Trucut biopsy or when Trucut biopsy is not 
possible. 
It is done for lesions smaller than 4 cm in size. 
It provides complete histo-pathological diagnosis needed for treatment 
decision making. 
It may serve as a definite procedure in the form of lumpectomy for 
benign tumours. 
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v INCISION BIOPSY 
 It is an alternate to Trucut biopsy when it comes as inconclusive 
and there is strong suspicion of malignancy. 
 It is done for lesions larger than 4 cm in size.  
 A small bit of tissue in removed making an incision in the skin 
over the lump. 
 The incision must be carefully placed so that the scar must be 
included within the incision for definitive surgery. 
v STEREOTACTIC BIOPSY 
It is done under the guidance of mammography using a vacuum 
assisted core needle. 
The patient lies prone on a specially designed table for this 
procedure. 
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v SENTINEL LYMPH NODE BIOPSY 
Sentinel lymph node is the first lymph node to drain the tumour. 
 It can be localized by pre-operative or per operative injection of 
vital blue dye (lymphazurin) with Technetium 99 radioisotope labeled 
sulphur colloid near the tumour or into sub dermal plexus around the 
nipple. 
          The markers are visually detected as blue staining with hand held 
gamma- camera and is biopsied with a small incision made directly over 
it and sent for frozen section analysis. 
 If the sentinel node is negative for metastasis, then the chance of 
other nodes to get affected is found to be remote. 
  It has been found to have low false negativity rates and 
hence helps to avoid unnecessary axillary dissection if node is negative 
for metastatic deposits. 
 It  forms  a  part  of  the  staging  workup  in  cases  of  clinically  
imperceptible nodes to look for micro / macro metastasis. 
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STAGING WORKUP 
CHEST X RAY / CT CHEST 
Pleural effusion, Cannon-ball secondaries, Mediastinal lymph 
nodes. 
USG/CT ABDOMEN 
Liver metastasis, Ascites, Krukenberg tumour 
SKELETAL SURVEY / BONE SCAN 
Osteolytic secondaries 
LFT 
Mammogram of opposite breast 
FNAC of contralateral axillary nodes 
CA 15-3 / CEA  
  Elevated in metastatic breastcancer 
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TNM STAGING 
PRIMARY TUMOUR 
Tx : Primary tumour cannot be assessed 
T0 : No evidence of primary tumour 
Tis : Carcinoma in situ (DCIS , LCIS , Paget’s disease) 
T1 : Tumour ≤ 20 mm in greatest dimension 
T1mic : Tumour <1 mm in greatest dimension 
T1a : Tumour  >1 mm but ≤ 5 mm in greatest dimension 
T1b : Tumour  >5 mm but ≤ 10 mm in greatest dimension 
T1c : Tumour  >10 mm but  ≤ 20 mm in greatest dimension 
T2 : Tumour  > 2 cm but ≤ 5 cm in greatest dimension 
T3 : Tumour  > 5 cm in greatest dimension 
T4 :  Tumour  of  any  size  with  direct  involvement  of  chest  wall  and/or  
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skin; inflammatory carcinoma 
T4a : Extension to chest wall (ribs, intercostals, serratus  anterior) 
T4b : Extension to skin (ulceration/ satellite nodules/  
peau d’orange) 
      T4c : T4a + T4b 
T4d : Inflammatory carcinoma 
 
REGIONAL LYMPH NODES (CLINICAL) 
Nx : nodes cannot be assessed 
N0 : no regional nodes 
N1 : ipsilateral mobile axillary node 
N2a : ipsilateral axillary nodes fixed to one another or other structures 
N2b : clinically apparent internal mammary nodes in the absence of 
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clinically palpable axillary nodes 
N3a : ipsilateral infraclavicular nodes with or without axillary nodes 
N3b : ipsilateral internal mammary nodes and axillary nodes 
N3c : ipsilateral supraclavicular nodes with or without axillary or internal 
mammary nodes 
 
REGIONAL LYMPH NODES(PATHOLOGICAL) 
pNX: Regional lymph nodes cannot be assessed. 
pN0: No regional node metastasis detected histologically and no 
examination for  Isolated tumour cells. 
pN0(I-) : No regional node metastasis  histologically ; negative IHC 
pN0(I+) : Malignant cells in regional lymph nodes no greater than 0.2 
mm ( detected by H&E stain or IHC ) 
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pN0(mol-) : No regional node metastasis histologically ; negative 
molecular findings( RT–PCR ) 
pN0(mol+) : Positive molecular findings but no regional node metastasis 
detected by histology or IHC 
pN1:  metastasis in one to three axillary nodes and/or internal mammary 
nodes with microscopic disease detected by SLNBbut not clinically 
apparent  
pN1mi : Micrometastasis (>0.2 mm &/or >200 cells; none >2.0 mm) 
pN1a : Mets in 1-3 axillary nodes at least one > 2.0 mm 
pN1b : Mets in internal mammary nodes detected by SLNBbut not 
clinically 
pN1c : pN1a + pN1b 
pN2: metastasis in four to nine axillary nodes or in clinically apparent 
internal mammary nodes in the absence of axillary nodal metastasis. 
pN2a : Mets in 4-9 axillary nodes at least one > 2.0 mm 
 55 
 
pN2b : Mets in clinically detected internal mammary nodes in the 
absence ofaxillary nodes 
pN3: metastasis in 10 or more axillary nodes or in infraclavicular nodes 
or in clinically apparent internal mammary nodes in the presence of 
axillary nodes or in more than three axillary nodes with clinically 
negative micrometastasis in internal mammary nodes or in ipsilateral 
supraclavicular nodes. 
pN3a : Mets in ≥ 10 axillary nodes (at least one > 2 mm) or metastasis to 
infraclavicular nodes 
pN3b: Mets in clinically detected internal mammary nodes in the 
presence of one or more positive axillary nodes; or in > 3 axillary nodes 
& in internal mammary nodes detected by SLNB. 
pN3c: Metastasis in ipsilateral supraclavicular lymph node. 
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DISTANT METASTASIS 
 Mx: Metastasis cannot be assessed 
 M0: No distant metastasis 
 M1: Distant metastasis 
AJCC STAGE GROUPING 
STAGE T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 T1 N1mi M0 
IIA 
T0 
T1 N1 M0 
T2 N0 M0 
IIB 
T2 N1 M0 
T3 N0 M0 
IIIA 
T0 
T1 
T2 
 
N2 
 
M0 
T3 N1 N2 M0 
IIIB  T4 
N0 
N1 
N2 
 
M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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CLASSIFICATION BASED ON TNM STAGING 
w Early breast cancer 
 Stages IA, IB, IIA, IIB (T2 N1 M0) 
It includes tumours less than 5 cm in size with/without ipsilateral 
mobile axillary nodes in the absence of distant metastasis. 
w Locally advanced breast cancer 
 Stages IIB (T3 N0 M0), IIIA, IIIB, IIIC 
It includes tumours more than 5 cm in size; ipsilateral fixed axillary 
nodes or palpable internal mammary, infraclavicular or supraclavicular 
nodes; fixity to skin/chest wall; inflammatory carcinoma. 
w Metastatic breast cancer 
 Stage IV 
It includes tumours with distant metastasis irrespective of tumour 
size or nodal status.  
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MANCHESTERSTAGING 
STAGE 1: 
 Tumour confined to the breast; no muscle/chest wall/ nodal 
involvement. Skin involvement < tumour size. 
STAGE 2: 
 Tumour confined to the breast with the presence of palpable mobile 
axillary nodes. Skin involvement < tumour size. 
STAGE 3: 
 Tumour extends beyond the breast parenchyma.  
- Skin infiltration over a large area compared to the size of the 
breast or skin ulceration. 
- Fixation to underlying fascia or muscle. 
Axillary nodes, if palpable, are mobile. 
STAGE 4: 
 Tumour extends beyond the breast in the form of skin infiltration 
beyond the breast, chest wall fixation, fixed axillary nodes, palpable 
supraclavicular nodes, spread to opposite breast/axilla and presence of 
distant metastasis. 
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PROGNOSTIC FACTORS 
TUMOUR RELATED FACTORS 
• Axillary nodal status 
• Tumour size 
• Histological grade 
• Lympho-vascular invasion 
• Hormone receptor status 
• DNA content 
• Growth factor indicators – erb B2, EGFR 
• Factors related to growth rate – S-phase fraction, p53 
• Factors related to invasion – cathepsin D, collagenase 
• Factors related to cell adhesion – CD44 gp. 
The axillary nodal status and tumour size are the two most important 
factors determining the prognosis. 
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HOST RELATED FACTORS 
• Age 
• Menopausal status 
• Family history ( first degree relatives ) 
• Personal history of breast cancer 
• Nutrition 
• Immunosuppression  
• Prior chemo / radiotherapy 
AXILLARY NODAL STATUS 
 It is the single most important prognostic factor. 
 The 10 year survival rate is 75% for node negative disease but 
drops to 50% if 1-3 nodes are involved and to less than 25% if ≥ 4 nodes 
are involved. 
 Involvement of contralateral axillary nodes indicates metastatic 
breast cancer and very poor prognosis. 
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TUMOUR SIZE 
 It is the second most important prognostic factor. 
 Larger the size of the tumour, higher the recurrence rate and lower 
the disease free survival rate and hence poorer the prognosis. 
GRADE OF THE TUMOUR 
  Nottingham or Elston-Ellis modification of Scarff-Bloom-
Richardson system is commonly used for grading. 
 It takes into account 3 factors: tubule formation, nuclear 
pleomorphism and mitotic rate.  
 Each  is  assigned  a  value  of  1-3  points  and  the  final  score  is  
obtained by adding up the score for each of the 3 factors. 
 GRADE 1 (3-5 points) à well differentiated 
 GRADE 2 (6/7 points) à moderately differentiated 
 GRADE 3 (8/9 points) à poorly differentiated  
 Higher grade tumours need to be treated more aggressively and 
have worse survival rates. 
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RECEPTOR STATUS 
 Hormone receptor status is critical in determining the suitability for 
targeted therapy in patients with breast cancer before or following 
surgery. 
 The presence of receptors, namely ER, PR and Her2-neu, is 
determined by immunohistochemistry (IHC) method. 
 The breast cancer can be classified into 4 main types based on the 
receptor status as: 
- Luminal A, 
- Luminal B, 
- Her2/neu overexpression and  
- Basal-like/Triple negative. 
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MOLECULAR SUBTYPES 
MOLECULAR SUBTYPE 
CLINICO PATHOLOGIC  
DEFINITION 
LUMINAL – A 
Luminal-A like 
• ER + 
• HER 2 –ve 
• PR high  
• Ki67 low 
LUMINAL – B 
Luminal-B like (HER 2 negative) 
• ER + 
• HER 2 –ve 
• PR low or Ki67 high 
Luminal-B like (HER 2 positive) 
• ER + 
• HER 2 +ve 
• Any PR  or  any  Ki67  
HER 2 
OVEREXPRESSION 
HER 2positive ( non-luminal) 
• HER 2 positive 
• ER & PR absent 
BASAL – LIKE 
Triple negative 
• ER & PR absent ; HER 2 –ve 
 
 64 
 
 ER positive tumours depend on estrogen for their growth and thus 
can  be  treated  with  drugs  which  either  block  the  action  of  estrogen  or  
decrease its level in the blood. They tend to have a better prognosis. 
 Her2 positive tumours can be treated with targeted therapy against 
Her2/neu receptor and generally have a poorer prognosis. 
 Triple negative tumours have the worst prognosis. 
TUMOUR TYPE 
 Invasive Mucinous and tubular cancers have a better prognosis 
compared to comedo or NOS type. 
 Invasive lobular cancer has intermediate prognosis. 
 Invasive medullary cancer has a poor prognosis. 
TUMOUR STAGE 
 Higher the stage, worse the prognosis. 
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MANAGEMENT 
 The management of breast cancer is multimodal comprising of 
surgery, chemotherapy, radiotherapy, hormone therapy and targeted 
therapy. 
SURGERY 
 The various surgical methods include 
• Radical mastectomy 
• Modified radical mastectomy 
• Simple mastectomy 
• Breast conservation surgery. 
v RADICAL MASTECTOMY 
 It was first described by Halstead in 1894. 
It comprises of removal of the breast tissue with nipple-areolar 
complex, level I, II and III axillary nodes, pectoralis major and minor, 
subscapularis, portions of serratus anterior, lattissmus dorsi, external 
oblique and rectus muscles. 
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 The structures preserved include the axillary vessels and cephalic 
vein. 
§ Disadvantages: 
ü Highly mutilating surgery 
ü Shoulder fixation 
ü Lymphedema of arms 
ü Winging of scapula 
ü Poor cosmetic results 
It is seldom being done now-a-days. 
v MODIFIED RADICAL MASTECTOMY 
 It was first described by Patey in 1943. 
It comprises of removal of the entire breast tissue, nipple-areolar 
complex, skin over the breast, pectoralis minor muscle, level I to III 
nodes. 
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§ AUCHINCLOSS MODIFICATION: 
Pectoralis minor muscle retracted (preserved) and only level 
I and II nodes are removed. 
§ SCANLON MODIFICATION: 
 Pectoralis minor muscle cut at its insertion to remove level III 
nodes as well and sutured back. 
 The structures preserved include the axillary vessels, long thoracic 
nerve of Bell, thoracodorsal nerve, cephalic vein and pectoralis major 
muscle. 
 It is less morbid and cosmetically better and provides good 
vascular bed for reconstruction compared to the radical mastectomy. 
 Adequate axillary clearance is when more than ten axillary nodes 
are present in the resected specimen and the presence of more than 4 
positive nodes indicates poor prognosis. 
 It is the most common surgery being performed for carcinoma 
nowadays. 
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v SIMPLE MASTECTOMY 
 It involves removal of whole breast with nipple areolar complex 
 Sentinel node surgery for axillary staging may be done through 
same or separate incision. 
 It is done prophylactically in carriers of familial breast cancer gene 
mutations (BRCA1 and BRCA2) 
• TOILET MASTECTOMY 
Done in locally advanced fungating or ulcerated breast 
cancer for improving the morbidity. 
v BREAST CONSERVATION SURGERY 
 It was first introduced in 1981. 
 It is being used in the management of early breast cancer {stage 1 
and 2}. 
 It  comprises  of  removal  of  the  lump  with  adequate  margin  of  
clearance, assessment of axillary nodal status and post-operative 
radiotherapy. 
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 It may be in the form of wide local excision, quadrantectomy and 
partial mastectomy. 
§ WIDE LOCAL EXCISION: 
Removal of the tumour with a rim of 1 cm of normal breast 
tissue followed by radiotherapy. 
§ QUADRANTECTOMY: 
Removal of the quadrant of the breast containing the tumour.  
§ PARTIAL/SEGMENTAL MASTECTOMY: 
Removal of the tumour along with some amount of 
surrounding normal breast tissue and the fascia over the 
underlying muscle. 
§ QUART THERAPY OF VERONESI: 
It comprises of Quadrantectomy, Axillary node dissection 
and Radiotherapy. 
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 The indications for breast conservation surgery include smaller 
monocentric  tumours,  small  size  of  the  tumour  relative  to  that  of  the  
breast, patients’ compliance for adjuvant radiotherapy. 
 The contraindications include large tumour size, multicentric 
tumours, diffuse micro calcifications, pregnancy, familial breast cancer, 
previously irradiated chest wall, invasive lobular carcinoma, LCIS, 
collagen vascular diseases. 
 It is cosmetically superior to MRM and being considered as a 
standard treatment for early stage breast cancer. 
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BREAST RECONSTRUCTION 
 It is done following mastectomy to improve the cosmetic 
appearance of the chest. 
 It can be done using 
§ Breast implants 
Made of silicone and placed subcutaneously or 
subpectorally. 
§ Tissue expanders 
§ Flaps 
- Lattissmus dorsi flap 
- TRAM flap (transverse rectus abdominis 
myocutaneous flap) à pedicle or free flap based on 
superior or inferior epigastric arteries respectively. 
 The advent of microsurgical techniques have made free flaps a 
standard mode of reconstruction. 
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CHEMOTHERAPY 
 It can be adjuvant (given after surgery) or Neoadjuvant (given 
before surgery). 
 Neoadjuvant therapy is useful in downsizing locally advanced 
cancers to improve the resectability and also helps to assess the response 
of the tumour to the chemotherapeutic agents. It is usually given for 3 
cycles. 
 Adjuvant chemotherapy is indicated for 
- All node positive cancers, 
- Tumours larger than 1 cm in size, 
- Hormone nonresponsive/ receptor negative tumours. 
It is given for 6 cycles. 
 Palliative chemotherapy is indicated in widespread metastatic 
breast cancer. 
 The chemotherapeutic agents used are broadly divided into 
Anthracyclines and non- Anthracyclines. 
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 The commonly used chemotherapeutic regimens include FAC (5-
fluorouracil, Adriamycin and cyclophosphamide) and CEF 
(cyclophosphamide, epirubicin and 5-fluorouracil). 
RADIOTHERAPY 
Indications: 
w Positive resection margins 
w Following breast conservation surgery 
w Chest wall involvement 
w For internal mammary nodes 
w When axillary clearance is not done 
w For metastasis (bone , brain) 
 It is contraindicated to axilla following axillary dissection due to 
increased risk of lymphedema of arms. 
 Adverse effects: 
w lymphedema of arms 
w cancer-en-cuirase 
w lymphangiosarcoma (Stewart Treves syndrome) 
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Dose: 5000-6000 cGy units (to chest wall) 
200 cGy per day for 5 days a week for 5-6 weeks (to the axilla - 
when dissection has not been done) 
HORMONE THERAPY 
 It is indicated in receptor positive breast cancers. 
v TAMOXIFEN 
• It is a Selective Estrogen Receptor Modulator. 
• It has Anti-estrogen action in the breast & agonistic action 
elsewhere. 
• It acts by blocking cytosolic estrogen receptors. 
• Its Half-life is 7 days and takes 4 weeks to show its effects. 
• It also reduces cholesterol levels & cardiovascular morbidity.  
• It is used for adjuvant hormone therapy in premenopausal women 
with ER positive breast cancer. 
• Its dosage is 10 mg BID or 20 mg OD orally for5 years. 
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• Other  drugs  with  similar  mechanism  of  action  are  Raloxifene, 
Ormeloxifene. 
• Adverse effects 
- Tamoxifen flare(flushing,sweating,vaginal dryness, itching). 
- Bone pain and weight gain. 
- Increased incidence of endometrial cancer. 
- Increased risk for DVT (3%). 
- Increased incidence of pulmonary embolism, CVA, TIA, 
cataract, fractures. 
LETROZOLE 
• It is a non-steroidal competitive inhibitor of enzyme “aromatase” 
which converts adrenal androgens to estrogens – ‘Aromatase 
Inhibitor.’ 
• Other drugs with similar action include Anastrazole and 
Exemestane (steroidal). 
• It is used as adjuvant endocrine therapy in post-menopausal women 
with hormone responsive breast cancer. 
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• It is also useful in metastatic & recurrent cases. 
• It slows down & stops the growth of estrogen sensitive breast 
tumours by reducing estrogen level by up to 98%. 
• Half-life is 45 hours. 
• It decreases the bone density. 
• Its dosage is2.5mg once daily orally for 5 years. 
• Side effects  
 Vaginal dryness, night sweats, hot flushes, vaginal bleeding, 
cardiovascular problems & osteoporosis. 
The other modes of hormonal therapy include 
ü GnRH analogues (goserelin, buserelin) 
ü Ovarian ablation 
ü Oophorectomy 
ü Adrenalectomy 
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TARGETED THERAPY 
v TRASTUZUMAB (HERCEPTIN): 
• It is a recombinant humanized monoclonal antibody that blocks 
HER-2/Neu receptors thereby preventing the growth of cancer 
cells. 
• Used in combination with chemotherapy in Her2 positive breast 
cancers. 
• It is given by IV infusion: 4mg/kg as loading dose&2mg/kg as 
maintenance dose weeklyalong with Chemotherapy & then 
6mg/kgonce in 3 weeksfor 1 year. 
• Its main side effect is Cardiomyopathy especially when 
combined with anthracycline based chemotherapy. 
v LAPATINIB 
 It is an EGF receptor antagonist that can be used in Metastatic 
disease in combination with Trastuzumab. 
v BEVACIZUMAB 
 It is a VEGF receptor antagonist recently being tried in breast 
cancer. 
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TREATMENT APPROACH 
LCIS 
 Observation with or without Tamoxifen. 
DCIS 
 Mastectomy àif widespread involvement 
 Wide excision + radiotherapy àfor limited disease 
EARLY BREAST CANCER 
i. MRM + adjuvant chemotherapy + radiotherapy 
    OR 
ii. Breast conservation surgery + assessment of axillary nodal 
status + radiotherapy  
§ Adjuvant Hormone therapy is given based on receptor 
status positivity. 
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LOCALLY ADVANCED BREAST CANCER 
If operable  
i. MRM + adjuvant chemotherapy + radiotherapy 
    OR 
ii. Neoadjuvant chemotherapy + MRM + adjuvant 
chemotherapy + radiotherapy 
If inoperable 
 Neoadjuvant chemotherapy + MRM if possible + adjuvant 
chemotherapy + radiotherapy. 
§ Adjuvant Hormone therapy is given based on receptor status 
positivity and usually after completion of chemotherapy. 
§ Trastuzumab/Herceptin can be given in Her2 positive 
tumours concurrently with chemotherapy.  
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LOCOREGIONAL RECURRENCE 
 
ET – endocrine therapy 
   CT – chemotherapy 
 RT – radiotherapy  
LOCOREGIONAL 
RECURRENCE
AFTER BCS
( WITHIN 
BREAST )
MASTECTOMY
AFTER MRM
(WITHOUT 
ADJUVANT RT) 
COMPLETE 
EXCISION + 
LOCOREGIONAL 
RADIOTHERAPY
ADJUVANT 
ET/CT/HER 2-
DIRECTED 
THERAPY
AFTER MRM 
(WITH  
ADJUVANT RT)
COMPLETE 
EXCISION ± RE-
IRRADIATION TO 
LIMITED AREAS
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METASTATIC BREAST CANCER 
w Palliative Simple mastectomy if ulcerated / fungated followed 
by Radiotherapy. 
w Hormone therapy if ER+ 
w Bisphosphonates for bone metastasis. 
w Herceptin à for Her2-neu positive tumours  
w Chemotherapy à 
a. ER negative cancers,  
b. Symptomatic visceral metastasis, 
c. Hormone non responsive metastasis. 
w Radiotherapy à 
ü Painful bone metastasis 
ü Brain metastasis 
ü Painful or fungating soft tissue masses 
 
 
 
 
 
 
MATERIALS 
AND 
METHODS 
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MATERIALS AND METHODS 
This is a prospective and retrospective study done in patients with 
biopsy proven carcinoma breast who had undergone Mastectomy in Rajiv 
Gandhi Government General Hospital. 
Inclusion criteria: 
 All women with carcinoma breast who had undergone mastectomy 
in Rajiv Gandhi Government General Hospital in the past 2 years and 
their resected specimen tested for receptor status by pathologists. 
Exclusion criteria: 
 Those patients in whom the receptor status of mastectomy 
specimen was not studied or not available. 
Sample size: 200 patients 
Parameters studied: Estrogen receptor, Progesterone receptor, Her2/neu 
receptor by using special kits. 
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OBSERVATION AND ANALYSIS 
AGE DISTRIBUTION 
AGE GROUP (years) NO. OF PATIENTS 
21-30 3 
31-40 70 
41-50 64 
51-60 44 
61-70 16 
71-80 3 
 
BASED ON MENSTRUAL STATUS 
Premenopausal – 120 patients 
Postmenopausal – 80 patients 
 84 
 
 
 Most of the patients belonged to the age groups 31-40 yrs (70 pts), 
41-50 yrs (64pts) and 51-60 yrs (44 pts).  
 
 
3
70
64
44
16
3
0
10
20
30
40
50
60
70
80
21-30 31-40 41-50 51-60 61-70 71-80
no
 o
f p
at
ie
nt
s
age group (in years)
AGE DISTRIBUTION
120
80
MENSTRUAL STATUS
PREMENOPAUSAL
POSTMENOPAUSAL
 85 
 
HORMONE RECEPTOR STATUS 
 
AGE 
GROU
P 
(YRS) 
ER+ 
PR- 
HER2
- 
ER- 
PR+ 
HER2
- 
ER- 
PR- 
HER2
+ 
ER+ 
PR+ 
HER2
- 
ER+ 
PR- 
HER2
+ 
ER- 
PR+ 
HER2
+ 
ER+ 
PR+ 
HER2
+ 
ER- 
PR-
HER2
- 
21-30 1 - - 2 - - - - 
31-40 23 5 10 10 6 5 3 8 
41-50 24 4 3 4 7 5 4 13 
51-60 9 8 5 5 4 6 1 6 
61-70 5 - 2 2 2 1 - 4 
71-80 1 - - - 1 - - 1 
TOTAL 63 17 20 23 20 17 8 32 
  
The most common type was found to be ER+ PR- Her2- and the 
least common was Triple Positive type. 
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 Estrogen Receptor alone was positive in 63 patients. It was 
common in age groups 41-50 yrs and 31-40 yrs. 
 
 
 
 
 
1
23
24
9
5
1
0
5
10
15
20
25
30
21-30 31-40 41-50 51-60 61-70 71-80
N
o 
of
 p
at
ie
nt
s
age group
ER+  PR- HER2-
 89 
 
 
 
 
Progesterone Receptor alone was positive in 17 patients. It was 
seen in age groups 51-60 yrs, 31-40 yrs and 41-50 yrs. 
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 Her2 neu receptor alone was positive in 20 cases. It was most 
common in the age group 31-40 years (50% cases). 
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 Both ER and PR were positive in 26 cases and the highest was in 
the age group 31-40 years (almost 40%). 
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 Both ER and Her2/neu receptor were positive in 20 patients. The 
highest was among the age groups 41-50 yrs (35%) & 31-40 yrs (30%). 
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 Both PR and Her2 neu receptor were positive in 17 cases. The 
highest was among the age group 51-60 yrs (6 cases) followed by 41-50 
and 31-40 yrs (5 cases each). 
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 All the three receptors were found to be positive in 8 cases with the 
highest being in the age group 41-50 yrs (4 cases) followed by 31-40 yrs 
(3 cases) and 51-60 yrs (1 case). 
 
 
 
0
3
4
1
0 0
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
21-30 31-40 41-50 51-60 61-70 71-80
no
 o
f p
at
ie
nt
s
age group
ER+  PR+  HER2+
 95 
 
 
 
 
  Triple negative cancers contributed to 32 cases (16%). The 
highest was in the age group 41-50 years (13) followed by 31-40 yrs (8) 
and 51-60 yrs (6). 
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RECEPTOR DISTRIBUTION BASED ON MENSTRUAL STATUS 
Menstrual 
status 
ER+ 
PR- 
HER
2- 
ER- 
PR+ 
HER
2- 
ER- 
PR- 
HER
2+ 
ER+ 
PR+ 
HER
2- 
ER+ 
PR- 
HER
2+ 
ER- 
PR+ 
HER
2+ 
ER+ 
PR+ 
HER
2+ 
ER- 
PR-
HER
2- 
Pre 
menopausal 
44 7 12 14 12 9 6 16 
Post 
menopausal 
19 10 8 9 8 8 2 16 
Total 63 17 20 23 20 17 8 32 
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w Estrogen receptors were positive in 57% of the study population. 
w Progesterone receptors were positive in 32.5% of the study population. 
w Her2-neu receptors were positive in 32.5% of the study population.  
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w The relative proportion of estrogen receptor positivity was high 
among premenopausal women whereas that of progesterone 
receptor was comparatively high among postmenopausal women. 
w Her2 neu receptor was almost equally distributed among the two 
groups. 
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w The incidence of estrogen receptor is high in pre-menopausal age 
group whereas that of progesterone receptor status in 
postmenopausal women.  
w Her2/neu receptor is equally distributed between the two groups.  
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DISCUSSION 
 The study aims at determining the incidence of receptor positive 
status in the mastectomy specimen of women operated for breast cancer 
in our hospital. 
 200 women who had been operated for breast cancer were selected 
for my study. Out of them, 120 (60%) were premenopausal women and 
80 (40%) were postmenopausal women. 
 As per published literature, the incidence of receptor positivity 
varies in people of different races and ethnicity. The incidence of 
Estrogen and Progesterone receptor positivity increases with age and this 
is greater for progesterone than for estrogen receptors. Her2 positive and 
triple negative cancers tend to present at an earlier age. 
 In my study, the overall receptor positivity rate including both 
individual and combined status were 57% , 32.5% and 32.5% for ER, PR, 
HER2/neu receptors respectively.  
 Overall,  the  most  common  subtype  was  ER+  PR-  HER2-  
contributing 31.5% of cases. The least common type was Triple positive 
accounting for 4% of cases. The same was true for either of the two 
groups as well. 
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 ER+ tumours were more common in the younger age groups 
(100% in 21-30 yrs, 61% in 41-50 yrs, 60% in 31-40 yrs.) and also in 71-
80 years (67%). 
 PR+ tumours were common in the age groups 21-30 yrs (67%), 51-
60 yrs (45%), 31-40 yrs (33%) and 41-50 years (27%). 
 Her2/neu positive tumours were almost equally distributed in all 
age groups contributing around 30% in each (except in 21-30 age group 
in whom none were positive). 
 Triple negative tumours contributed for 16% of all cases. 
 ER positivity was proportionately more among premenopausal 
women (63.33% vs 47.5%), whereas   PR positivity was proportionately 
more among postmenopausal women (36.25% vs 30%). Her2/neu 
receptors were equally distributed among both the groups (32.5%). 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
Ø The incidence of Estrogen receptor positivity was found to be 57%. 
It was higher in premenopausal women (63.33%), whereas in 
postmenopausal women it was 47.5%. 
Ø The incidence of Progesterone receptor positivity was 32.5%. It was 
higher in postmenopausal women (36.25%) compared to 
premenopausal women (30%) 
Ø The incidence of Her2/neu receptor positivity was found to be 
32.5%. It was equally distributed in premenopausal and 
postmenopausal women (32.5%). 
Ø The most common receptor subtype was ER+ve, PR-ve, Her2/neu-
ve contributing 31.5%. 
Ø The least common receptor subtype was Triple positive constituting 
4%. 
Ø The incidence of Triple negative receptor status was found to be 
16%. 
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PROFORMA 
Name:   Age:     Sex: 
IP No.: 
DOA:      DOP:    DOD: 
Diagnosis: 
Procedure Done: 
On examination:  
General condition: 
VITALS: 
PR:                             BP:                           RR:                        
CVS: 
 
RS: 
 
P/A: 
  
 
SPECIMEN: 
 
HISTO-PATHOLOGICAL EXAMINATION: 
 
RECEPTOR STATUS: 
 
Investigation parameters: 
 
 
ER  
PR  
HER-2/neu  
 
 
  
Post-Operative Complications: 
Wound infection: 
Seroma formation: 
Flap necrosis: 
 
Condition on discharge: 
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